<DOC>
	<DOCNO>NCT00782548</DOCNO>
	<brief_summary>The primary objective study compare single-dose relative bioavailability Alpharma Branded Products Division ( Kadian® ) Ligand® Pharmaceuticals Inc. ( AVINZA® ) 30 mg morphine sulfate sustained-release capsule healthy adult volunteer feed condition . The secondary objective study evaluate adverse event associate 2 different morphine sulfate modified-release commercial formulation</brief_summary>
	<brief_title>Comparative Study Evaluate KADIAN Avinza Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<criteria>Inclusion criterion : Healthy adult nonsmoker , moderate smoker ( less 10 cigarette per day least 3 month ) exsmoker ( smoke least 3 month ) male female volunteer , 19 40 year age . Weighing least 60 kg male 52 kg female within 15 % ideal weight ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) . Medically healthy subject clinically significant abnormality laboratory profile ECGs , deem Principal Investigator . Females childbearing potential either sexually inactive ( abstinent ) 14 day prior first dose throughout study use one follow acceptable birth control method : 1. surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum . 2 . IUD place least 3 month ; 3. barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose throughout study ; 4. surgical sterilization partner ( vasectomy 6 month minimum ) ; 5. hormonal contraceptive least 3 month prior first dose study . Other birth control method may deem acceptable . Postmenopausal woman amenorrhea &gt; 2 year , confirm blood testing . Voluntarily consent participate study . Exclusion criterion : History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : 1. alcoholism drug abuse within past 2 year ; 2. asthma chronic respiratory illness ; 3. gastrointestinal dysmobility recent enteritis ; 4. hypersensitivity idiosyncratic reaction morphine opioids ; 5. hypersensitivity idiosyncratic reaction naltrexone , naloxone , narcotic antagonist . Female subject pregnant lactating . Subjects surgery gastrointestinal tract ( except appendectomy ) would interfere absorption study drug Subjects receive hepatic enzyme induce drug ( e.g . Nizoral® , Tagamet® ) within previous three month Subjects whose sit blood pressure le 110/60 mm Hg screen 100/55 mm Hg dosing . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study . Subjects make donation ( standard donation amount ) blood blood product ( exception plasma note ) within 56 day prior study . Subjects make plasma donation within 7 day prior study . Subjects hemoglobin less 12.0 g/dL . Subjects participate another clinical trial within 28 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>KADIAN</keyword>
	<keyword>morphine</keyword>
	<keyword>Avinza</keyword>
	<keyword>30 mg</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>fed</keyword>
</DOC>